Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Sensei Biotherapeutics (SNSE) announced initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug, a ...
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...
The variable domain gene usage was diverse in these monoclonal antibodies. SAN DIEGO — An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha ...
Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation. Given the current uncertainties and risks, I rate ...
SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Get Instant Summarized Text (Gist) Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), significantly reduces nasal polyps and congestion in patients with severe ...
The Business Research Company Updated 2025 Market Reports have released and offer essential trends and forecasts up to 2034. Early purchase is your competitive edge! LONDON, GREATER LONDON, UNITED KIN ...
The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an ... immuno-oncology and checkpoint inhibitor antibodies licensed from the Dana-Farber Cancer Institute that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback